Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Research context
Jafron Biomedical Co.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Jafron Biomedical Co.,Ltd is currently in a long term uptrend where the price is trading 4.7% above its 200 day moving average.
From a valuation standpoint, the stock is 264.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 35.1.
Jafron Biomedical Co.,Ltd's total revenue rose by 38.0% to $635M since the same quarter in the previous year.
Its net income has increased by 62.1% to $248M since the same quarter in the previous year.
Finally, its free cash flow grew by 99.4% to $320M since the same quarter in the previous year.
Based on the above factors, Jafron Biomedical Co.,Ltd gets an overall score of 4/5.